210
Participants
Start Date
November 16, 2024
Primary Completion Date
February 28, 2026
Study Completion Date
May 31, 2026
Lerodalcibep
PCSK9 inhibitor
matching placebo
placebo
NOT_YET_RECRUITING
Peking University First Hospital, Beijing
RECRUITING
Beijing Anzhen Hospital of Capital Medical University, Beijing
RECRUITING
Beijing Luhe Hospital, Capital Medical Univeristy, Beijing
RECRUITING
Beijing Tsinghua Changgeng Hospital, Beijing
RECRUITING
Fuwai Hospital, CAMS & PUMC, Beijing
RECRUITING
Guangdong Provincial People's Hospital, Guangzhou
RECRUITING
Shijiazhuang People's Hospital, Shijiazhuang
RECRUITING
Daqingshi People's Hospital, Daqing
RECRUITING
The 2nd Xiangya Hospital of Central South University, Changsha
RECRUITING
The Third Xiangya Hospital of Central South University, Changsha
RECRUITING
Nanchang People's Hospital, Nanchang
RECRUITING
Binzhou Medical University Hospital, Binzhou
RECRUITING
Heze Municipal Hospital, Heze
RECRUITING
Qilu Hospital of Shandong University, Jinan
RECRUITING
Zibo Municipal Hospital, Zibo
RECRUITING
West China Hospital of Sichuan University, Chengdu
RECRUITING
Tianjin People's Hospital, Tianjin
RECRUITING
The First Affiliated Hospital of Wenzhou Medical Univesity, Wenzhou
Lead Sponsor
Hasten Biopharmaceutical Co., Ltd.
INDUSTRY